Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MDM2 | Q00987 | 14/20 | 0.50 |
| ▸ | TP53 | P04637 | 6/20 | 0.48 |
| ▸ | RAF1 | P04049 | 3/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756028 | 0.86 | ALDH1A1 (0.59) | ALDH1A1MDM2TP53RAF1BRAF | |
| SCHEMBL3756756 | 0.85 | MDM2 (0.53) | ALDH1A1MDM2TP53KCNH2SCN5A | |
| SCHEMBL2027394 | 0.77 | ALDH1A1 (0.72) | ALDH1A1MDM2TP53RAF1BRAF | |
| SCHEMBL14397918 | 0.77 | THRB (0.53) | ALDH1A1TP53 | |
| SCHEMBL14399108 | 0.74 | THRB (0.53) | ALDH1A1TP53RAF1BRAF | |
| SCHEMBL14399102 | 0.73 | THRB (0.55) | ALDH1A1TP53 | |
| SCHEMBL2022118 | 0.73 | ALDH1A1 (0.66) | ALDH1A1MDM2TP53RAF1BRAF | |
| SCHEMBL14397943 | 0.73 | THRB (0.52) | ALDH1A1TP53 | |
| SCHEMBL2029430 | 0.73 | ALDH1A1 (0.61) | ALDH1A1MDM2TP53RAF1BRAF | |
| SCHEMBL3745820 | 0.73 | MDM2 (0.51) | ALDH1A1MDM2TP53KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | ALDH1A1 315/4885MDM2 3686/4885TP53 3912/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | ALDH1A1 310/4885MDM2 3351/4885TP53 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.